Avenue Therapeutics Inc. has reported its financial results for the three months ending March 31, 2025. The company experienced an operating loss of $1.905 million, compared to a larger loss of $3.708 million during the same period in 2024. Operating expenses were impacted by a decline in research and development costs, which decreased to $411,000 from $2.392 million in the previous year. General and administrative expenses increased slightly to $1.494 million from $1.316 million. Additionally, the company recorded other income, including an interest income of $32,000 compared to $49,000 in the previous year, and a change in the fair value of warrant liabilities resulting in an income of $15,000 compared to a loss of $116,000 last year. A notable update in Avenue Therapeutics' business operations is the termination and transfer agreement with AnnJi, which was finalized on April 24, 2025. Further details about this agreement are available in Note 3 of their financial statement.